NCI-H929 (H929) xenograft model of human MM

NCI-H929 (H929) cells (5 × 10⁶) were injected subcutaneously into the right dorsal flank of sublethally irradiated (2 Gy) female SCID mice on day 1. Human pan-T cells expanded in vitro (5 × 10⁶; T-cell isolation, activation/expansion kits from Miltenyi Biotec) were injected intraperitoneally on day 12 into preallocated animals. The animals were randomized into treatment groups on day 15 based on tumor size (group mean tumor volume ∼260 mm³) and treatment with AMG 701, len, or both was initiated on the same day (supplemental Figure 7A). AMG 701 (0.25 mg/kg per administration) was administered by lateral tail vein once weekly starting on day 15 for 5 weeks. len (0.2 mg/kg per administration) was administered intraperitoneally once daily from days 15 to 46. Tumor growth was monitored by external caliper measurements, and tumor volumes were calculated) sing a standard hemiellipsoid formula. Values represent mean tumor sizes (in mm³) ± standard error of the mean (SEM). The study was terminated at day 47. Mice were euthanized when tumor diameter exceeded 15 mm in size. All animal studies were conducted under approved institutional animal care and use committee protocols in Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)–accredited facilities and in accordance with the German Animal Welfare Law with permission from the local authorities and within the guidelines of AAALAC international standards.